Pharmaceuticals

Aclaris Therap

Aclaris Therapeutics released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 1.996 M (forecast USD 1.322 M), actual EPS USD -0.1539 (forecast USD -0.1577)

Aclaris Therap released FY2025 earnings on February 26 (EST), actual revenue USD 7.826 M (forecast USD 7.991 M), actual EPS USD -0.5297 (forecast USD -0.5262)

Aclaris Therapeutics released FY2025 Q4 earnings on February 26, 2026 (EST), actual revenue USD 1.295 M (forecast USD 2.071 M), actual EPS USD -0.1613 (forecast USD -0.145)

Aclaris Therapeutics Expands Inflammation and Immunology Pipeline and Updates Strategy

Aclaris Therapeutics released FY2025 Q3 earnings on November 6, 2025 (EST), actual revenue USD 3.299M (forecast USD 1.405M), actual EPS USD -0.1191 (forecast USD -0.135)

Aclaris Therapeutics released FY2025 9-month earnings on November 6, 2025 (EST), with actual revenue of USD 6.531 M and actual EPS of USD -0.3691

TR | OpenAI – 4o Downgrades Aclaris Therapeutics Rating to Sell

Amin Analyzes Healthcare Stocks, Giving Aclaris Therapeutics a Moderate Buy Rating

Aclaris Therapeutics to Hold R&D Day to Showcase Innovative Therapies

Aclaris Therap released FY2025 Semi-Annual earnings on August 7, 2025 (EST) with actual revenue of USD 3.232 M and EPS of USD -0.2491

Aclaris Therapeutics released FY2025 Q2 earnings on August 7 (EST), actual revenue USD 1.777 M (forecast USD 1.287 M), actual EPS USD -0.1258 (forecast USD -0.13)

Aclaris to Present New Immunoinflammatory Therapies at Virtual Conference

Aclaris Initiates ATI-052 Clinical Trial

Wedbush Reiterates Outperform Rating on Aclaris

Aclaris Therapeutics Launches Clinical Trial for New Bispecific Antibody ATI-052

Aclaris Holds Annual Shareholders' Meeting and Elects Three Directors

Aclaris Therapeutics CEO Joins HC Wainwright Event

Aclaris Therapeutics released FY2025 Q1 earnings on May 8 (EST), actual revenue USD 1.455 M (forecast USD 3.55 M), actual EPS USD -0.1232 (forecast USD -0.1675)

Aclaris Therap Announces 2025 Q1 Earnings and Future Plans

Aclaris Therapeutics Inc Expected to Report 12-Cent Loss Per Share

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

ACRS

Earnings Watch

Aclaris Therap | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 1.996 M

ATRX

PHOE

ARKG

LABU

SBIO

Phoenix Asia Holdings Limited shares rose 0.19% on Thursday following the announcement of a $1 billion stock acquisition of ACEA Pharma. This deal, involving 100 million newly-issued shares at $10 each, is expected to close by Q2 2026, pending regulatory approvals. The acquisition aims to expand Phoenix Asia's footprint in the pharmaceutical sector, potentially creating new revenue streams. Despite mixed market conditions, the stock's momentum remains bullish, although it trades at a premium compared to peers, indicating potential valuation risks for investors.

benzinga_article

Adhera Therapeutics, Inc.

Phoenix Asia

SPDR S&P Biotech

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

VG Health

iShares Global Healthcare

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

NASDAQ Composite Index

S&P 500

Dow Jones Industrial Average

Why Is Phoenix Asia Stock Gaining Today?

Craig-Hallum analyst Adam Vogel has maintained a Buy rating on Aclaris Therapeutics (ACRS) with a price target of $10.00. Vogel, who focuses on the Healthcare sector, has an average return of 28.1% and a 93.75% success rate on his stock recommendations. Additionally, Piper Sandler also holds a Buy rating on Aclaris with a price target of $11.00.

Tip Ranks

iShares US Pharma

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

LB Pharmaceuticals

Apogee Therapeutic

Piper Sandler Cos

Aclaris Therapeutics (ACRS) Gets a Buy from Craig-Hallum

Aclaris Therap | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 1.996 M

Guggenheim has upgraded Aclaris Therapeutics (NASDAQ: ACRS) to a "strong-buy" rating. The stock has seen mixed ratings from analysts, with two giving a strong buy, five a buy, and one a sell. Aclaris has a market cap of $663.39 million and a current price of $4.75, with a one-year high of $4.89. The company reported a quarterly loss of $0.16 EPS, missing estimates. Recent insider trading saw major shareholder Braden Michael Leonard sell 300,000 shares. Institutional investors hold 98.34% of the stock, indicating strong institutional interest.

Market Beat

UBS Group AG

Nasdaq

JPMorgan Chase

Bank of NY Mellon

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

BANK OF NEW YORK MELLON CORP DEP SHS REPG 1/4000TH INT SER K PFD

Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Upgraded by Guggenheim

KALU

SION

AMAT

BMEA

Top Wall Street analysts have initiated coverage on several companies with varying ratings. Seaport Global's Jay Goldberg rated Applied Materials (AMAT) as Buy with a $500 target. Citizens' Jonathan Wolleben rated Biomea Fusion (BMEA) as Market Outperform with a $9 target. Guggenheim's Seamus Fernandez rated Aclaris Therapeutics (ACRS) as Buy with a $12 target. UBS's Alex Stansbury rated Kaiser Aluminum (KALU) as Neutral with a $176 target. Wedbush's Laura Chico rated Sionna Therapeutics (SION) as Outperform with a $53 target.

Kaiser Aluminum

Sionna Therapeutics

Applied Materials

Biomea Fusion

Shutterstock

This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Aclaris Therapeutics (NASDAQ: ACRS) announced updates on its clinical programs, revealing full results from the Phase I-A study of ATI-052 and plans to advance ATI-2138 into a Phase IIb trial for lichen planus. The Phase I-A study confirmed pharmacokinetic and pharmacodynamic data, showing promising results in safety and efficacy. Aclaris is also initiating Phase I-B trials for atopic dermatitis and asthma, with top-line data expected in 2026. The company aims to enhance efficacy measures and has selected lichen planus for further development of ATI-2138.

Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen Planus

Aclaris Therap(ACRS.US)